View More Recent Stories

May 27, 2025 08:05AM Palvella Therapeutics (PVLA) Appoints Ashley Kline as Chief Commercial Officer

Apr 22, 2025 07:30AM Palvella Therapeutics (PVLA) Granted Additional U.S. Patent for QTORIN Rapamycin for the Treatment of Microcystic Lymphatic Malformations

Apr 9, 2025 06:13AM Chardan Capital Markets Starts Palvella Therapeutics (PVLA) at Buy

Apr 2, 2025 07:04AM Smid cap biotech investors must stop chasing binary events says Cantor Fitzgerald

Mar 31, 2025 11:32AM Stifel Reiterates Buy Rating on Palvella Therapeutics (PVLA)

Mar 25, 2025 04:07PM Stifel Starts Palvella Therapeutics (PVLA) at Buy

Mar 24, 2025 04:12PM Jones Trading Starts Palvella Therapeutics (PVLA) at Buy

Mar 18, 2025 06:42AM Lucid Capital Markets Starts Palvella Therapeutics (PVLA) at Buy, PT $49

Mar 7, 2025 07:11AM Scotiabank Starts Palvella Therapeutics (PVLA) at Sector Outperform

Feb 11, 2025 06:47AM H.C. Wainwright Reiterates Buy Rating on Palvella Therapeutics (PVLA)

Feb 5, 2025 05:29AM TD Cowen Starts Palvella Therapeutics (PVLA) at Buy

Jan 10, 2025 08:05AM Palvella Therapeutics (PVLA) Announces Publication of Results from Phase 2 Clinical Trial of QTORIN™ 3.9% Rapamycin Anhydrous Gel for the Treatment of Microcystic Lymphatic Malformations in the Jour

Jan 3, 2025 06:07AM H.C. Wainwright Reiterates Buy Rating on Palvella Therapeutics (PVLA)

Dec 31, 2024 06:12AM Palvella Therapeutics (PVLA) Files for 5.63M Share Offering by Selling Stockholders

Dec 26, 2024 06:29AM H.C. Wainwright Starts Palvella Therapeutics (PVLA) at Buy

View More Recent Stories